Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$160 Mln
P/E Ratio
--
P/B Ratio
1.37
Industry P/E
--
Debt to Equity
0.06
ROE
-0.52 %
ROCE
-49.35 %
Div. Yield
0 %
Book Value
3.37
EPS
-2.12
CFO
$-90.84 Mln
EBITDA
$-123.75 Mln
Net Profit
$-119.94 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
908 Devices (MASS)
| 116.14 | 15.69 | 63.97 | -17.88 | -37.03 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
908 Devices (MASS)
| -80.13 | 47.24 | -70.55 | -54.57 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.10 | 10,391.68 | 14.66 | 12.69 | |
| 71.01 | 9,766.86 | 94.68 | 2.52 | |
| 277.35 | 10,728.90 | 770.42 | 1.2 | |
| 117.67 | 14,455.82 | 41.45 | 5.44 |
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products... include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210 Read more
Co-Founder, CEO, President & Director
Dr. Kevin J. Knopp Ph.D.
Co-Founder, CEO, President & Director
Dr. Kevin J. Knopp Ph.D.
Headquarters
Boston, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of 908 Devices Inc (MASS) stood at $ 159 Mln as on 31-Dec-24
The share price of 908 Devices Inc (MASS) is $4.76 (NASDAQ) as of 17-Apr-2025 16:15 EDT. 908 Devices Inc (MASS) has given a return of -37.03% in the last 3 years.
908 Devices Inc (MASS) has a market capitalisation of $ 160 Mln as on 17-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of 908 Devices Inc (MASS) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the 908 Devices Inc (MASS) and enter the required number of quantities and click on buy to purchase the shares of 908 Devices Inc (MASS).
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Address: 645 Summer Street, Boston, MA, United States, 02210
The CEO & director of Dr. Kevin J. Knopp Ph.D.. is 908 Devices Inc (MASS), and CFO & Sr. VP is Dr. Kevin J. Knopp Ph.D..
There is no promoter pledging in 908 Devices Inc (MASS).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,126
|
|
|
1,070
|
|
|
1,049
|
|
|
978
|
| 908 Devices Inc. (MASS) | Ratios |
|---|---|
|
Return on equity(%)
|
-51.56
|
|
Operating margin(%)
|
-121.56
|
|
Net Margin(%)
|
-121.09
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of 908 Devices Inc (MASS) was $0 Mln.
$0.23
(
